TY  - JOUR
A1  - Deak, Dalma
A1  - Pop, Cristina
A1  - Zimta, Alina-Andreea
A1  - Jurj, Ancuta
A1  - Ghiaur, Alexandra
A1  - Pasca, Sergiu
A1  - Teodorescu, Patric
A1  - Dascalescu, Angela
A1  - Antohe, Ion
A1  - Ionescu, Bogdan
A1  - Constantinescu, Catalin
A1  - Onaciu, Anca
A1  - Munteanu, Raluca
A1  - Berindan-Neagoe, Ioana
A1  - Petrushev, Bobe
A1  - Turcas, Cristina
A1  - Iluta, Sabina
A1  - Selicean, Cristina
A1  - Zdrenghea, Mihnea
A1  - Tanase, Alina
A1  - Danaila, Catalin
A1  - Colita, Anca
A1  - Colita, Andrei
A1  - Dima, Delia
A1  - Coriu, Daniel
A1  - Einsele, Hermann
A1  - Tomuleasa, Ciprian
T1  - Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia
JF  - Frontiers in Immunology
N2  - Background: Therapy for acute lymphoblastic leukemia (ALL) are currently initially efficient, but even if a high percentage of patients have an initial complete remission (CR), most of them relapse. Recent data shows that immunotherapy with either bispecific T-cell engagers (BiTEs) of chimeric antigen receptor (CAR) T cells can eliminate residual chemotherapy-resistant B-ALL cells.
Objective: The objective of the manuscript is to present improvements in the clinical outcome for chemotherapy-resistant ALL in the real-life setting, by describing Romania's experience with bispecific antibodies for B-cell ALL.
Methods: We present the role of novel therapies for relapsed B-cell ALL, including the drugs under investigation in phase I-III clinical trials, as a potential bridge to transplant. Blinatumomab is presented in a critical review, presenting both the advantages of this drug, as well as its limitations.
Results: Bispecific antibodies are discussed, describing the clinical trials that resulted in its approval by the FDA and EMA. The real-life setting for relapsed B-cell ALL is described and we present the patients treated with blinatumomab in Romania.
Conclusion: In the current manuscript, we present blinatumomab as a therapeutic alternative in the bridge-to-transplant setting for refractory or relapsed ALL, to gain a better understanding of the available therapies and evidence-based data for these patients in 2019.
KW  - blinatumoman
KW  - acute lymphoblastic leukemia
KW  - bridge-to-transplant
KW  - real life setting
KW  - bispecific antobodies
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193921
SN  - 1664-3224
VL  - 10
IS  - 2856
ER  -